Sanofi-Aventis Sees Diversifying In China As Key To Success; Expands Capacity For Diabetes Treatment Lantus
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sanofi-Aventis announced a series of expansion plans in China aimed at diversifying its portfolio, the CEO said April 21 during his first trip to China
You may also be interested in...
Lilly Presses On In China With Manufacturing Expansion In Suzhou And Partnership With Novast
Just two weeks after Lilly opened its diabetes R&D center in Shanghai, the company announced the opening of a second manufacturing site in Suzhou and an outsourcing manufacturing partnership with Novast in Nantong.
Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country
Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country